M L Dahl

Role of CYP2C9 polymorphism in losartan oxidation.

Ümit Yaşar, Gunnel Tybring, Mats Hidestrand et al. · PubMed · 2001 · 151 citations

Medicine, Pharmacokinetics, Pharmacology +16

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

Anna‐Karin Hamberg, Mia Wadelius, Jonatan D. Lindh et al. · Clinical Pharmacology & Therapeutics · 2010 · 96 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

M.G. Scordo, Edoardo Spina, Placido Romeo et al. · European Journal of Clinical Pharmacology · 2000 · 75 citations

Medicine, Pharmacokinetics, Pharmacology +16

Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.

Agneta Wennerholm, Inger Johansson, Amos Massele et al. · PubMed · 1999 · 75 citations

Medicine, Genetics, Pharmacology +17

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype

M L Dahl, Leif Bertilsson, Conny Nordin · Psychopharmacology · 1996 · 74 citations

Medicine, Pharmacokinetics, Pharmacology +13